Compare SER & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | BDSX |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | SER | BDSX |
|---|---|---|
| Price | $1.51 | $17.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.00 | ★ $32.50 |
| AVG Volume (30 Days) | 80.3K | ★ 153.6K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | $134.46 | $23.35 |
| Revenue Next Year | N/A | $19.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.42 | $0.25 |
| 52 Week High | $7.92 | $20.21 |
| Indicator | SER | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 36.51 | 62.47 |
| Support Level | N/A | $6.33 |
| Resistance Level | $1.86 | N/A |
| Average True Range (ATR) | 0.12 | 1.84 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 21.32 | 65.98 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.